Overall verdict
Buy
6.5/10
1-year performance
+31.03%
Score breakdown
Up 31.0% over 1 year, 97% of the 52-week range.
Strongest: Profitability 9.2/10. Weakest: Growth 5.0/10.
23 analysts, target +0.0% vs the price.
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates through three segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets. The Life Sciences and Diagnostics Markets segment offers liquid chromatography systems and components; and liquid chromatography mass spectrometry systems.
This segment is also involved in the genomics, contract development and manufacturing organization, pathology, companion diagnostics, and biomolecular analysis businesses. The Agilent CrossLab segment provides various services, including repairs, parts, maintenance, installations, training, compliance support, software as a service, asset management, consulting, and other custom services. This segment also offers consumables, including gas chromatography and liquid chromatography columns, sample preparation products, custom chemistries, and various laboratory supplies ;
software and informatics solutions comprising software for instrument control, data acquisition, data analysis, secure storage of results, and laboratory information and workflow management ; and OpenLab laboratory software, an open software platform that enables customers to capture, analyze, and share scientific data throughout the lab and across the enterprise. In addition, it provides automated sample preparation solutions, such as liquid handling, plate management, consumables, and scheduling software.
The Applied Markets segment offers products in the areas of gas chromatography, mass spectrometry, spectroscopy, vacuum technology, and remarketed instruments. It markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.
Sector
Health Care
Industry
Life Sciences Tools and Services
Primary listing
Nyse
United States
CEO
Padraig McDonnell
Founded
1999
Employees
18 100
Revenue / employee
383 867 USD
Next earnings
November 25, 2026 (estimated)
Institutional holders
- BlackRock, Inc.9.48%
- VANGUARD CAPITAL MANAGEMENT LLC6.84%
- VANGUARD PORTFOLIO MANAGEMENT LLC5.35%
- STATE STREET CORP4.76%
- MASSACHUSETTS FINANCIAL SERVICES CO /MA/3.71%
- T. Rowe Price Investment Management, Inc.2.87%
- GEODE CAPITAL MANAGEMENT, LLC2.81%
- WELLINGTON MANAGEMENT GROUP LLP2.76%
- DEUTSCHE BANK AG\2.60%
- Other institutions55.10%
- Rest of the register3.72%
1128 13F filings as of June 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
174.77 USD
52-week low
108.35 USD
1-year performance
31.03%
Rising
Year-to-date performance
21.34%
Rising
Drawdown
-1.20%
Near its high
Position in the 52-week range
97% of range
Against the world ETF
Over 17 years, from September 2009 to August 2026, the share did not do better than the world ETF once risk is accounted for. It earned more, but shaking 2.2 times harder: for the risk taken, the ETF paid better.
10,000 € placed at the end of September 2009 are worth today
| Agilent Technologies | 109 803 € |
| World ETF | 74 620 € |
| S&P 500 | 123 025 € |
| Risk-free placement | 11 288 € |
The risk
- Shaking:the share moves 2.2 times as much as the world ETF.
- Worst fall:-42 % between November 2022 and April 2025. 10,000 € placed at the top fell to 5 810 €. The world ETF, at worst: -34 %. The share has not returned to its high yet.
Agilent Technologies earned more than the world ETF since 2009
Value of 10,000 euros placed at the end of September 2009, dividends reinvested, in euros
- Agilent Technologies: 109 803 €
- World ETF: 74 620 €
- S&P 500: 123 025 €
- Risk-free placement: 11 288 €
Based on past performance. This is not a recommendation.
Range: 117.04 USD - 149.42 USD (comparables only)
The price implies growth of 12.97% per year; the company grows at 14.68%.
Gross margin 53.7%, net margin 19.5%, ROIC 13.9%, ROE 21.0%.
Net margin
19.53%
Exceptional
Sector 5.47%|S&P 12.97%
Gross margin
53.72%
High
Return on equity (ROE)
20.97%
Exceptional
Sector 3.01%|S&P 16.52%
Return on invested capital (ROIC)
13.89%
Exceptional
Free cash flow margin (FCF)
17.19%
Exceptional
Profit-to-cash conversion (FCF conversion)
0.88x
High
Margin stability
4.3 pts
Steady
Revenue to net income
Growth
5.0/10Revenue up 8.1% over 1 year, 5.4% a year over 5, EPS 14.7% a year over 5.
Revenue (trailing 12 months)
7.4Md USD
Revenue growth (1y)
8.06%
Solid
Revenue growth (3y)
1.46%
Moderate
EPS growth (1y)
8.50%
Moderate
EPS CAGR (5y)
14.68%
Strong
EPS revisions (3 months)
2.33%
Revised up
Valuation
5.2/10P/E 34.0x, forward P/E 33.6x, EV/EBITDA 25.4x, PEG 2.32. The multiple sits in the 93th percentile of its own 5-year history.
P/E (TTM)
34.0x
Fair
Sector 51.0x|S&P 23.0x
Forward P/E
33.6x
Fair
EV / EBITDA
25.4x
Fair
Sector 28.4x|S&P 14.5x
PEG
2.32
Very expensive
Sector 1.76|S&P 0.86
Fair value (reverse DCF)
133.23 USD
Overvalued
P/E vs its own 5-year history
among the 7% highest valuations
At its historical high
Market cap
46.6Md USD
Financial strength
8.6/10Cash covers 44.5% of the debt, net debt/EBITDA 0.9x.
Net debt / EBITDA
0.9x
Solid
Gearing (net debt / equity)
29.76%
Very solid
Cash
1.8Md USD
Cash / market cap
3.77%
Tight
Cash / total debt
44.52%
Solid
Interest coverage
15.5x
Very solid
Net debt
2.2Md USD
Equity
7.4Md USD
Closed daily candles, 2 years
Last close on September 24, 2026: 172.84 USD
- MM20153.99
- MM50148.01
- MM200131.93
- RSI 1475.2
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+0.42%
200-day average slope, 3 months
+1.10%
50-day average slope, 1 month
+6.87%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
2.08 % per day
Volatility change
-3.44%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 5.13 (9) | 6.20 (22) | 7 501 (21) | 2 209 (17) | 1 456 (8) |
| 2027 | 6.03 (11) | 6.76 (23) | 7 986 (22) | 2 413 (17) | 1 675 (9) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of September 21, 2026.
Same sub-industry: 103 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 603259 | 8.0 | 8.0 | 75.1Md USD | 22.2x | 40.2 % | 47.7 % | 29.5 % | -1.7x | 2.6 % | 56.1 % | ||
| 2 | A207940 | 7.5 | 7.9 | 46.0Md USD | 31.8x | 39.9 % | 30.2 % | 16.6 % | -0.2x | 2.3 % | -13.0 % | ||
| 3 | IQV | 6.8 | 7.0 | 44.1Md USD | 33.2x | 8.1 % | 8.8 % | 6.8 % | 4.1x | 5.0 % | 47.6 % | ||
| 4 | A | 6.5 | 6.8 | 46.6Md USD | 34.0x | 19.5 % | 8.1 % | 13.9 % | 0.9x | 2.7 % | 31.0 % | ||
| 5 | DHR | 6.4 | 6.5 | 156Md USD | 39.3x | 15.9 % | 5.5 % | 5.4 % | 2.0x | 3.5 % | 18.6 % | ||
| 6 | LONN | 6.3 | 6.1 | 46.4Md USD | Not meaningful (loss) | 16.7 % | 19.2 % | 8.7 % | 1.9x | 0.6 % | 6.1 % | ||
| 7 | TMO | 5.9 | 5.7 | 246Md USD | 35.8x | 15.0 % | 10.5 % | 7.9 % | 2.8x | 3.0 % | 45.0 % | ||
| 8 | ILMN | 4.9 | 5.1 | 38.6Md USD | 47.6x | 18.4 % | 9.8 % | 18.2 % | 0.8x | 2.4 % | 175.3 % | ||
| 9 | WAT | 4.8 | 3.8 | 41.3Md USD | 105.0x | 3.6 % | 113.3 % | 1.4 % | 0.8x | 0.9 % | 44.7 % |
